Lymphoma News

Tumor gene expression profiles have become standard practice to help guide treatment of several cancer types.

The FDA granted orphan drug designation to nanatinostat and valganciclovir for treatment of Epstein Barr virus-positive diffuse large B-cell lymphoma not otherwise specified.

The FDA granted regenerative medicine advanced therapy designation to CTX110, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.

In certain settings.

Sepsis is a leading cause of preventable death across the globe, and patients with cancer have a 10 times higher likelihood of developing this life-threatening condition than those without cancer.

COVID-19 remains a significant global burden, with 5 million worldwide deaths recorded as of October, according to a speaker at Chemotherapy Foundation Symposium.

Targeted therapies have rapidly changed the treatment landscape of indolent non-Hodgkin lymphoma, a heterogenous group of diseases for which individualized care is crucial, according to a speaker at Chemotherapy Foundation Symposium.

The FDA granted fast track designation to EZM0414 for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.

Management of cancer therapies in the era of COVID-19 infection and vaccination requires careful consideration of both disease and patient characteristics, according to members of a crossfire panel at Chemotherapy Foundation Symposium.

Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study.